Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer

Phase 2 Completed 34 enrolled New Mexico Cancer Research Alliance Fred Hutchinson Cancer Center · collab Novartis · collab

NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the clinical efficacy of combining Gleevec (imatinib mesylate), a PDGFR antagonist, with front-line, single-agent paclitaxel in a cohort of elderly patients with advanced, non-small cell lung cancer.

Timeline

Start: 2009-08
Primary completion: 2011-07
Completion: 2012-07

Outcome

Met primary endpoint

paper Overall RR was 11/34 (32%; 95% CI 17%-51%), meeting the primary endpoint. PMID 23033932 ↗

Publications

Results Bauman JE, Eaton KD, Wallace SG, Carr LL, Lee SJ, Jones DV, Arias-Pulido H, Cerilli LA, Martins RG. A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer. BMC Cancer. 2012 Oct 3;12:449. doi: 10.1186/1471-2407-12-449.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Imatinib	Small molecule	600 mg	Oral
Subject	Paclitaxel	Small molecule	90 mg/m2	Intravenous